Group 1 - The United States and Switzerland have reached a new tariff agreement, reducing tariffs from 39% to 15%, with Switzerland committing to invest approximately $200 billion in the U.S. by the end of 2028 [1][2] - The total investment includes commitments from Swiss pharmaceutical companies Roche ($50 billion) and Novartis ($23 billion), as well as investments from engineering group ABB and railway equipment manufacturer Stadler [1] - The agreement must be approved by the Swiss parliament and will subsequently undergo a national referendum, with the Swiss government emphasizing the need to lower costs for domestic companies [1][2] Group 2 - The tariff negotiations are critically important for Switzerland, as the U.S. is a major export market for Swiss goods such as watches, chocolate, pharmaceuticals, and machine tools [2] - The recent tariff crisis has led to a significant decline in Swiss technology exports to the U.S., with a reported drop of 14.2% in the third quarter compared to the previous year [1] - The economic impact of the tariffs has prompted discussions about Switzerland's neutral status and increased calls for strengthening relations with the European Union [2]